TY - JOUR
T1 - Differentiation-inducing factor-3 inhibits intestinal tumor growth in vitro and in vivo
AU - Kubokura, Naoya
AU - Takahashi-Yanaga, Fumi
AU - Arioka, Masaki
AU - Yoshihara, Tatsuya
AU - Igawa, Kazunobu
AU - Tomooka, Katsuhiko
AU - Morimoto, Sachio
AU - Nakatsu, Yoshimichi
AU - Tsuzuki, Teruhisa
AU - Nakabeppu, Yusaku
AU - Matsumoto, Takayuki
AU - Kitazono, Takanari
AU - Sasaguri, Toshiyuki
N1 - Funding Information:
This work was supported by Kakenhi grants from the Japan Society for the Promotion of Science ( 21590284 and 25460334 to FTY).
Publisher Copyright:
© 2015 The Authors.
PY - 2015
Y1 - 2015
N2 - Differentiation-inducing factor-1 (DIF-1) produced by Dictyostelium discoideum strongly inhibits the proliferation of various types of cancer cells by suppression of the Wnt/β-catenin signal transduction pathway. In the present study, we examined the effect of differentiation-inducing factor-3 (DIF-3), a monochlorinated metabolite of DIF-1 that is also produced by D. discoideum, on human colon cancer cell lines HCT-116 and DLD-1. DIF-3 strongly inhibited cell proliferation by arresting the cell cycle at the G0/G1 phase. DIF-3 reduced the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β in a time and dose-dependent manner. In addition, DIF-3 suppressed the expression of T-cell factor 7-like 2, a key transcription factor in the Wnt/β-catenin signaling pathway, thereby reducing the mRNA levels of cyclin D1 and c-Myc. Subsequently, we examined the in vivo effects of DIF-3 in Mutyh-/- mice with oxidative stress-induced intestinal cancers. Repeated oral administration of DIF-3 markedly reduced the number and size of cancers at a level comparable to that of DIF-1. These data suggest that DIF-3 inhibits intestinal cancer cell proliferation in vitro and in vivo, probably by mechanisms similar to those identified in DIF-1 actions, and that DIF-3 may be a potential novel anti-cancer agent.
AB - Differentiation-inducing factor-1 (DIF-1) produced by Dictyostelium discoideum strongly inhibits the proliferation of various types of cancer cells by suppression of the Wnt/β-catenin signal transduction pathway. In the present study, we examined the effect of differentiation-inducing factor-3 (DIF-3), a monochlorinated metabolite of DIF-1 that is also produced by D. discoideum, on human colon cancer cell lines HCT-116 and DLD-1. DIF-3 strongly inhibited cell proliferation by arresting the cell cycle at the G0/G1 phase. DIF-3 reduced the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β in a time and dose-dependent manner. In addition, DIF-3 suppressed the expression of T-cell factor 7-like 2, a key transcription factor in the Wnt/β-catenin signaling pathway, thereby reducing the mRNA levels of cyclin D1 and c-Myc. Subsequently, we examined the in vivo effects of DIF-3 in Mutyh-/- mice with oxidative stress-induced intestinal cancers. Repeated oral administration of DIF-3 markedly reduced the number and size of cancers at a level comparable to that of DIF-1. These data suggest that DIF-3 inhibits intestinal cancer cell proliferation in vitro and in vivo, probably by mechanisms similar to those identified in DIF-1 actions, and that DIF-3 may be a potential novel anti-cancer agent.
UR - http://www.scopus.com/inward/record.url?scp=84938514386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938514386&partnerID=8YFLogxK
U2 - 10.1016/j.jphs.2015.03.005
DO - 10.1016/j.jphs.2015.03.005
M3 - Article
C2 - 25913757
AN - SCOPUS:84938514386
SN - 1347-8613
VL - 127
SP - 446
EP - 455
JO - Journal of Pharmacological Sciences
JF - Journal of Pharmacological Sciences
IS - 4
ER -